Cargando…

Percutaneous ablation of pancreatic cancer

Pancreatic ductal adenocarcinoma is a highly aggressive tumor with an overall 5-year survival rate of less than 5%. Prognosis and treatment depend on whether the tumor is resectable or not, which mostly depends on how quickly the diagnosis is made. Chemotherapy and radiotherapy can be both used in c...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Onofrio, Mirko, Ciaravino, Valentina, De Robertis, Riccardo, Barbi, Emilio, Salvia, Roberto, Girelli, Roberto, Paiella, Salvatore, Gasparini, Camilla, Cardobi, Nicolò, Bassi, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124972/
https://www.ncbi.nlm.nih.gov/pubmed/27956791
http://dx.doi.org/10.3748/wjg.v22.i44.9661
_version_ 1782469909669740544
author D’Onofrio, Mirko
Ciaravino, Valentina
De Robertis, Riccardo
Barbi, Emilio
Salvia, Roberto
Girelli, Roberto
Paiella, Salvatore
Gasparini, Camilla
Cardobi, Nicolò
Bassi, Claudio
author_facet D’Onofrio, Mirko
Ciaravino, Valentina
De Robertis, Riccardo
Barbi, Emilio
Salvia, Roberto
Girelli, Roberto
Paiella, Salvatore
Gasparini, Camilla
Cardobi, Nicolò
Bassi, Claudio
author_sort D’Onofrio, Mirko
collection PubMed
description Pancreatic ductal adenocarcinoma is a highly aggressive tumor with an overall 5-year survival rate of less than 5%. Prognosis and treatment depend on whether the tumor is resectable or not, which mostly depends on how quickly the diagnosis is made. Chemotherapy and radiotherapy can be both used in cases of non-resectable pancreatic cancer. In cases of pancreatic neoplasm that is locally advanced, non-resectable, but non-metastatic, it is possible to apply percutaneous treatments that are able to induce tumor cytoreduction. The aim of this article will be to describe the multiple currently available treatment techniques (radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation), their results, and their possible complications, with the aid of a literature review.
format Online
Article
Text
id pubmed-5124972
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-51249722016-12-12 Percutaneous ablation of pancreatic cancer D’Onofrio, Mirko Ciaravino, Valentina De Robertis, Riccardo Barbi, Emilio Salvia, Roberto Girelli, Roberto Paiella, Salvatore Gasparini, Camilla Cardobi, Nicolò Bassi, Claudio World J Gastroenterol Editorial Pancreatic ductal adenocarcinoma is a highly aggressive tumor with an overall 5-year survival rate of less than 5%. Prognosis and treatment depend on whether the tumor is resectable or not, which mostly depends on how quickly the diagnosis is made. Chemotherapy and radiotherapy can be both used in cases of non-resectable pancreatic cancer. In cases of pancreatic neoplasm that is locally advanced, non-resectable, but non-metastatic, it is possible to apply percutaneous treatments that are able to induce tumor cytoreduction. The aim of this article will be to describe the multiple currently available treatment techniques (radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation), their results, and their possible complications, with the aid of a literature review. Baishideng Publishing Group Inc 2016-11-28 2016-11-28 /pmc/articles/PMC5124972/ /pubmed/27956791 http://dx.doi.org/10.3748/wjg.v22.i44.9661 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Editorial
D’Onofrio, Mirko
Ciaravino, Valentina
De Robertis, Riccardo
Barbi, Emilio
Salvia, Roberto
Girelli, Roberto
Paiella, Salvatore
Gasparini, Camilla
Cardobi, Nicolò
Bassi, Claudio
Percutaneous ablation of pancreatic cancer
title Percutaneous ablation of pancreatic cancer
title_full Percutaneous ablation of pancreatic cancer
title_fullStr Percutaneous ablation of pancreatic cancer
title_full_unstemmed Percutaneous ablation of pancreatic cancer
title_short Percutaneous ablation of pancreatic cancer
title_sort percutaneous ablation of pancreatic cancer
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124972/
https://www.ncbi.nlm.nih.gov/pubmed/27956791
http://dx.doi.org/10.3748/wjg.v22.i44.9661
work_keys_str_mv AT donofriomirko percutaneousablationofpancreaticcancer
AT ciaravinovalentina percutaneousablationofpancreaticcancer
AT derobertisriccardo percutaneousablationofpancreaticcancer
AT barbiemilio percutaneousablationofpancreaticcancer
AT salviaroberto percutaneousablationofpancreaticcancer
AT girelliroberto percutaneousablationofpancreaticcancer
AT paiellasalvatore percutaneousablationofpancreaticcancer
AT gasparinicamilla percutaneousablationofpancreaticcancer
AT cardobinicolo percutaneousablationofpancreaticcancer
AT bassiclaudio percutaneousablationofpancreaticcancer